Elsevier

Brain Research

Volume 738, Issue 2, 4 November 1996, Pages 353-356
Brain Research

Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats

https://doi.org/10.1016/S0006-8993(96)01049-9Get rights and content

Abstract

The present study tested if a positive modulator of AMPA-type glutamate receptors would counteract the behavioral effects of a drug that enhances the release of dopamine. BDP-29, a compound shown to increase AMPA receptor-mediated synaptic responses in hippocampal slices, markedly attenuated the amount of stereotypic rearings seen in rats after methamphetamine injections. These results suggest that AMPA receptor modulators ameliorate certain aberrant, dopamine-related behaviors and hence may be of interest with regard to schizophrenia.

References (28)

  • BogertsB. et al.

    Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage

    Arch. Gen. Psychol.

    (1985)
  • ClineschmidtB.V. et al.

    Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties

    Drug Dev. Res.

    (1982)
  • CreeseI. et al.

    Dopamine receptor binding predicts clinical and pharmacological potencies of anti schizophrenic drugs

    Science

    (1976)
  • FreedW.J. et al.

    Neuropharmacological studies of phencyclidine (PCP)-induced behavioral stimulation in mice

    Psychopharmacology

    (1980)
  • Cited by (41)

    • Partial effects of the AMPAkine CX717 in a strain specific battery of tests for manic-like behavior in black Swiss mice

      2015, Pharmacological Reports
      Citation Excerpt :

      Control group for each experiment was treated with the same volume of 33% HPCD solution. AMPAkines were repeatedly demonstrated to cross the blood brain barrier after peripheral administration [28] and enter the brain within minutes [44]. To the best of our knowledge, the effects of CX717 on affective-like behavior in animals were not previously reported but the compound was shown to restore primate impaired cognitive performance caused by sleep deprivation [45].

    • NMDA receptors in the medial prefrontal cortex and the dorsal hippocampus regulate methamphetamine-induced hyperactivity and extracellular amino acid release in mice

      2012, Behavioural Brain Research
      Citation Excerpt :

      Indeed, there are moderate projections between the mPFC and dorsal/ventral hippocampal structure, including the entorhinal cortex, and the mPFC may regulate hippocampal function via the thalamus [69–72]. The present study shows that the MAP-induced increase of Glu release in the mPFC and Glu decrease in the DHC were inhibited by KA or NMDA lesions, which is consistent with other reports [73,74]. Thus, the increased Glu was blocked by NMDA lesion of the DHC after 140 min with MAP, but the KA lesion was still inhibited until the end of this experiment.

    • Glutamate-based therapeutic approaches: Ampakines

      2006, Current Opinion in Pharmacology
    • AMPA receptor modulators as cognitive enhancers

      2004, Current Opinion in Pharmacology
    • Schizophrenia as a disorder of neuroplasticity

      2004, International Review of Neurobiology
    View all citing articles on Scopus
    View full text